Outcomes of Vdpace for Relapsed/Refractory Multiple Myeloma in the Era of Daratumumab Based Therapy

被引：0
|
作者：
Venkatesh, Priyanka [1 ,2 ]
Khasawneh, Ghena [1 ,3 ]
Hashmi, Hamza [1 ,4 ]
Alkharabsheh, Omar [1 ,5 ]
Paul, Barry [1 ,6 ]
Skikne, Barry S. [1 ,7 ]
Mahmoudjafari, Zahra [1 ,7 ]
Ahmed, Nausheen [1 ,7 ]
Abdallah, Al-Ola [1 ,7 ]
Atrash, Shebli [1 ,6 ]
机构：
[1] US Myeloma Innovat Res Collaborat USMIRC, Kansas City, KS USA
[2] Univ Kansas, Internal Med, Med Ctr, Kansas City, KS USA
[3] Jordan Univ Sci & Technol, Irbid, Jordan
[4] Med Univ South Carolina, Hollings Canc Ctr, Charleston, SC USA
[5] Univ S Alabama, Mobile, AL USA
[6] Atrium Hlth, Levine Canc Inst, Plasma Cell Disorders Sect, Dept Hematol Oncol & Blood Disorders, Charlotte, NC USA
[7] Univ Kansas, Div Hematol Malignancies & Cellular Therapeut, Med Ctr, Westwood, KS USA
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-188117
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Influence of Disease and Patient Characteristics on Daratumumab Exposure and Clinical Outcomes in Relapsed or Refractory Multiple Myeloma
    Xiaoyu Yan
    Pamela L. Clemens
    Thomas Puchalski
    Sagar Lonial
    Henk Lokhorst
    Peter M. Voorhees
    Saad Usmani
    Paul G. Richardson
    Torben Plesner
    Kevin Liu
    Robert Z. Orlowski
    Nedjad Losic
    Richard Jansson
    Tahamtan Ahmadi
    Kristen Lantz
    Juan Jose Perez Ruixo
    Honghui Zhou
    Xu Steven Xu
    Clinical Pharmacokinetics, 2018, 57 : 529 - 538
  • [32] Influence of Disease and Patient Characteristics on Daratumumab Exposure and Clinical Outcomes in Relapsed or Refractory Multiple Myeloma
    Yan, Xiaoyu
    Clemens, Pamela L.
    Puchalski, Thomas
    Lonial, Sagar
    Lokhorst, Henk
    Voorhees, Peter M.
    Usmani, Saad
    Richardson, Paul G.
    Plesner, Torben
    Liu, Kevin
    Orlowski, Robert Z.
    Losic, Nedjad
    Jansson, Richard
    Ahmadi, Tahamtan
    Lantz, Kristen
    Ruixo, Juan Jose Perez
    Zhou, Honghui
    Xu, Xu Steven
    CLINICAL PHARMACOKINETICS, 2018, 57 (04) : 529 - 538
  • [33] Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma
    Casneuf, Tineke
    Xu, Xu Steven
    Adams, Homer C., III
    Axel, Amy E.
    Chiu, Christopher
    Khan, Imran
    Ahmadi, Tahamtan
    Yan, Xiaoyu
    Lonial, Sagar
    Plesner, Torben
    Lokhorst, Henk M.
    van de Donk, Niels W. C. J.
    Clemens, Pamela L.
    Sasser, A. Kate
    BLOOD ADVANCES, 2017, 1 (23) : 2105 - 2114
  • [34] Real-world outcomes of daratumumab monotherapy in relapsed/refractory myeloma
    Maouche, N.
    Leary, H.
    Collings, F.
    Tseu, B.
    Djebbari, F.
    Vallance, G.
    Ramasamy, K.
    Kothari, J.
    BRITISH JOURNAL OF HAEMATOLOGY, 2020, 189 : 125 - 125
  • [35] NURSING IMPLICATIONS FOR PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA RECEIVING COMBINATION THERAPY WITH DARATUMUMAB (DARZALEX®).
    Catamero, Donna
    Morgan, Gillian
    Florendo, Erika
    ONCOLOGY NURSING FORUM, 2017, 44 (02)
  • [36] Melflufen Therapy for Relapsed Refractory Multiple Myeloma (RRMM) Patients Refractory to Daratumumab and/or Pomalidomide: A Report on Early Efficacy
    Mateos, Maria-Victoria
    Blade, Joan
    Larocca, Alessandra
    Oriol, Albert
    Rodriguez, Paula
    Alegre, Adrian
    Cavo, Michele
    Moreb, Jan S.
    Paner, Agne
    Gabrail, Nashat
    Halka, Kathleen G.
    Hassoun, Hani
    Maisel, Christopher
    Mazumder, Amitabha
    Zonder, Jeffrey A.
    Ocio, Enrique M.
    Byrne, Catriona
    Harmenberg, Johan
    Thuresson, Sara
    Nordstrom, Eva
    Lindberg, Jakob
    Richardson, Paul G.
    BLOOD, 2017, 130
  • [37] EFFECTIVENESS AND SAFETY ANALYSIS OF DARATUMUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA
    Kumar, Seri A.
    Fe, Bitaube R.
    Hinojosa, Orantos C.
    Gavira, Moreno R.
    Garzon, Lopez S.
    HAEMATOLOGICA, 2021, 106 (10) : 339 - 340
  • [38] Subcutaneous delivery of daratumumab in Japanese patients with relapsed/refractory multiple myeloma
    Shibayama, Hirohiko
    Matsumoto, Morio
    Kosugi, Hiroshi
    Shibayama, Kazuhiro
    Yamazaki, Hiroshi
    Iida, Shinsuke
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2021, 113 (01) : 112 - 121
  • [39] Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma
    Chari, Ajai
    Martinez-Lopez, Joaquin
    Mateos, Maria-Victoria
    Blade, Joan
    Benboubker, Lotfi
    Oriol, Albert
    Arnulf, Bertrand
    Rodriguez-Otero, Paula
    Pineiro, Luis
    Jakubowiak, Andrzej
    de Boer, Carla
    Wang, Jianping
    Clemens, Pamela L.
    Ukropec, Jon
    Schecter, Jordan
    Lonial, Sagar
    Moreau, Philippe
    BLOOD, 2019, 134 (05) : 421 - 431
  • [40] Practical considerations and role of Daratumumab retreatment for relapsed refractory Multiple Myeloma
    Kim, E. Bridget
    Harrington, Cynthia
    Yee, Andrew
    O'Donnell, Elizabeth
    Branagan, Andrew
    Burke, Jill
    Raje, Noopur
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E263 - E263
12345